OrganizationBiotech

National Cancer Institute (NCI)

Organization linked by public source evidence.

approved

Public IDs

No public external ID is attached.

Related people

No reviewed person affiliation is attached.

Outputs

No reviewed output is linked through affiliated people.

Topics

Cell and Synthetic BiologySourceClinicalTrials.gov SourceElsevier BVClinical and RegulatorySourceElsevier BV SourceClinicalTrials.govDiagnostics and BiomarkersSourceMDPI AG SourceClinicalTrials.govGenomics and Gene EditingSourceFrontiers Media SA SourceElsevier BVProtein and Drug DesignSourceInternational Journal of Newgen Research in Pharmacy & Healthcare SourceClinicalTrials.gov

Relationship evidence

Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial

Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial (NCT05947500)

PRODUCED BYincoming82% confidence

SourceClinicalTrials.gov

Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (NCT06015880)

PRODUCED BYincoming82% confidence

SourceClinicalTrials.gov

Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma

Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma (NCT03937830)

PRODUCED BYincoming82% confidence

SourceClinicalTrials.gov

Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S03)

Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S03) (NCT06611540)

PRODUCED BYincoming82% confidence

SourceClinicalTrials.gov

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) (NCT06694454)

PRODUCED BYincoming82% confidence

SourceClinicalTrials.gov

Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors

Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors (NCT01445509)

PRODUCED BYincoming82% confidence

SourceClinicalTrials.gov

Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)

Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP) (NCT05797246)

PRODUCED BYincoming82% confidence

SourceClinicalTrials.gov

Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)

Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST) (NCT04595747)

PRODUCED BYincoming82% confidence

SourceClinicalTrials.gov

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (NCT06172296)

PRODUCED BYincoming82% confidence

SourceClinicalTrials.gov

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer (NCT02502266)

PRODUCED BYincoming82% confidence

SourceClinicalTrials.gov

Timeline

No dated relationship evidence is attached.

Evidence statussource linked

Cross-source checkSingle reviewed source

SourceClinicalTrials.gov

AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study")

Publisher: ClinicalTrials.gov
Date: Jul 8, 2026
Trust tier: clinical-trials
License: ClinicalTrials.gov public registry record

SourceClinicalTrials.gov

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Publisher: ClinicalTrials.gov
Date: Jul 15, 2026
Trust tier: clinical-trials
License: ClinicalTrials.gov public registry record

SourceClinicalTrials.gov

Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04)

Publisher: ClinicalTrials.gov
Date: Jul 7, 2026
Trust tier: clinical-trials
License: ClinicalTrials.gov public registry record

SourceClinicalTrials.gov

Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial

Publisher: ClinicalTrials.gov
Date: Jul 10, 2026
Trust tier: clinical-trials
License: ClinicalTrials.gov public registry record

SourceClinicalTrials.gov

Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Publisher: ClinicalTrials.gov
Date: Jul 9, 2026
Trust tier: clinical-trials
License: ClinicalTrials.gov public registry record

SourceClinicalTrials.gov

Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma

Publisher: ClinicalTrials.gov
Date: Jun 30, 2026
Trust tier: clinical-trials
License: ClinicalTrials.gov public registry record

SourceClinicalTrials.gov

Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S03)

Publisher: ClinicalTrials.gov
Date: Jul 7, 2026
Trust tier: clinical-trials
License: ClinicalTrials.gov public registry record

SourceClinicalTrials.gov

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Publisher: ClinicalTrials.gov
Date: Jul 17, 2026
Trust tier: clinical-trials
License: ClinicalTrials.gov public registry record

SourceClinicalTrials.gov

Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors

Publisher: ClinicalTrials.gov
Date: Jul 16, 2026
Trust tier: clinical-trials
License: ClinicalTrials.gov public registry record

SourceClinicalTrials.gov

Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)

Publisher: ClinicalTrials.gov
Date: Jul 17, 2026
Trust tier: clinical-trials
License: ClinicalTrials.gov public registry record

SourceClinicalTrials.gov

Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)

Publisher: ClinicalTrials.gov
Date: Jul 16, 2026
Trust tier: clinical-trials
License: ClinicalTrials.gov public registry record

SourceClinicalTrials.gov

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

Publisher: ClinicalTrials.gov
Date: Jul 16, 2026
Trust tier: clinical-trials
License: ClinicalTrials.gov public registry record

SourceClinicalTrials.gov

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

Publisher: ClinicalTrials.gov
Date: Jul 1, 2026
Trust tier: clinical-trials
License: ClinicalTrials.gov public registry record

SourceClinicalTrials.gov

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer

Publisher: ClinicalTrials.gov
Date: Jul 9, 2026
Trust tier: clinical-trials
License: ClinicalTrials.gov public registry record

SourceClinicalTrials.gov

Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors

Publisher: ClinicalTrials.gov
Date: Jul 2, 2026
Trust tier: clinical-trials
License: ClinicalTrials.gov public registry record

SourceClinicalTrials.gov

Testing the Anti-Cancer Drug, Brenetafusp (IMCF106C), in Rare Cancers

Publisher: ClinicalTrials.gov
Date: Jul 7, 2026
Trust tier: clinical-trials
License: ClinicalTrials.gov public registry record

SourceClinicalTrials.gov

A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...

Publisher: ClinicalTrials.gov
Date: Jul 17, 2026
Trust tier: clinical-trials
License: ClinicalTrials.gov public registry record

SourceClinicalTrials.gov

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias

Publisher: ClinicalTrials.gov
Date: Jul 16, 2026
Trust tier: clinical-trials
License: ClinicalTrials.gov public registry record

SourceClinicalTrials.gov

Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

Publisher: ClinicalTrials.gov
Date: Jul 17, 2026
Trust tier: clinical-trials
License: ClinicalTrials.gov public registry record

SourceClinicalTrials.gov

Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial

Publisher: ClinicalTrials.gov
Date: Jul 8, 2026
Trust tier: clinical-trials
License: ClinicalTrials.gov public registry record

SourceClinicalTrials.gov

NCI COVID-19 in Cancer Patients, NCCAPS Study

Publisher: ClinicalTrials.gov
Date: Jul 2, 2026
Trust tier: clinical-trials
License: ClinicalTrials.gov public registry record

SourceClinicalTrials.gov

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Publisher: ClinicalTrials.gov
Date: Jul 13, 2026
Trust tier: clinical-trials
License: ClinicalTrials.gov public registry record

SourceClinicalTrials.gov

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

Publisher: ClinicalTrials.gov
Date: Jul 15, 2026
Trust tier: clinical-trials
License: ClinicalTrials.gov public registry record

SourceClinicalTrials.gov

Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse

Publisher: ClinicalTrials.gov
Date: Jul 8, 2026
Trust tier: clinical-trials
License: ClinicalTrials.gov public registry record

SourceClinicalTrials.gov

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Publisher: ClinicalTrials.gov
Date: Jul 13, 2026
Trust tier: clinical-trials
License: ClinicalTrials.gov public registry record

SourceClinicalTrials.gov

Biology Studies of Hematologic Cancers

Publisher: ClinicalTrials.gov
Date: Jul 16, 2026
Trust tier: clinical-trials
License: ClinicalTrials.gov public registry record

SourceClinicalTrials.gov

Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia

Publisher: ClinicalTrials.gov
Date: Jun 29, 2026
Trust tier: clinical-trials
License: ClinicalTrials.gov public registry record

SourceClinicalTrials.gov

IL-12 Genetically Engineered Myeloid Cells in Participants With Relapsed, Refractory Solid Tumors

Publisher: ClinicalTrials.gov
Date: Jul 17, 2026
Trust tier: clinical-trials
License: ClinicalTrials.gov public registry record

SourceClinicalTrials.gov

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

Publisher: ClinicalTrials.gov
Date: Jul 14, 2026
Trust tier: clinical-trials
License: ClinicalTrials.gov public registry record

SourceClinicalTrials.gov

Testing the Investigational Medication Pembrolizumab After Kidney Removal for Patients With Non-Clear Cell Renal Cell Carcinoma

Publisher: ClinicalTrials.gov
Date: Jul 8, 2026
Trust tier: clinical-trials
License: ClinicalTrials.gov public registry record

SourceClinicalTrials.gov

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Publisher: ClinicalTrials.gov
Date: Jul 10, 2026
Trust tier: clinical-trials
License: ClinicalTrials.gov public registry record

SourceClinicalTrials.gov

Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer

Publisher: ClinicalTrials.gov
Date: Jul 16, 2026
Trust tier: clinical-trials
License: ClinicalTrials.gov public registry record

SourceClinicalTrials.gov

Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma

Publisher: ClinicalTrials.gov
Date: Jul 8, 2026
Trust tier: clinical-trials
License: ClinicalTrials.gov public registry record

SourceClinicalTrials.gov

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

Publisher: ClinicalTrials.gov
Date: Jul 2, 2026
Trust tier: clinical-trials
License: ClinicalTrials.gov public registry record

SourceClinicalTrials.gov

Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery

Publisher: ClinicalTrials.gov
Date: Jul 15, 2026
Trust tier: clinical-trials
License: ClinicalTrials.gov public registry record

SourceClinicalTrials.gov

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Publisher: ClinicalTrials.gov
Date: Jul 17, 2026
Trust tier: clinical-trials
License: ClinicalTrials.gov public registry record

SourceClinicalTrials.gov

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

Publisher: ClinicalTrials.gov
Date: Jul 10, 2026
Trust tier: clinical-trials
License: ClinicalTrials.gov public registry record

SourceClinicalTrials.gov

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Publisher: ClinicalTrials.gov
Date: Jul 2, 2026
Trust tier: clinical-trials
License: ClinicalTrials.gov public registry record

SourceClinicalTrials.gov

Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

Publisher: ClinicalTrials.gov
Date: Jul 13, 2026
Trust tier: clinical-trials
License: ClinicalTrials.gov public registry record

SourceClinicalTrials.gov

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

Publisher: ClinicalTrials.gov
Date: Jul 2, 2026
Trust tier: clinical-trials
License: ClinicalTrials.gov public registry record

SourceClinicalTrials.gov

Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV

Publisher: ClinicalTrials.gov
Date: Jul 14, 2026
Trust tier: clinical-trials
License: ClinicalTrials.gov public registry record

SourceClinicalTrials.gov

Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation

Publisher: ClinicalTrials.gov
Date: Jul 17, 2026
Trust tier: clinical-trials
License: ClinicalTrials.gov public registry record

SourceClinicalTrials.gov

Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

Publisher: ClinicalTrials.gov
Date: Jun 30, 2026
Trust tier: clinical-trials
License: ClinicalTrials.gov public registry record

SourceClinicalTrials.gov

Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

Publisher: ClinicalTrials.gov
Date: Jul 17, 2026
Trust tier: clinical-trials
License: ClinicalTrials.gov public registry record

SourceClinicalTrials.gov

Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer

Publisher: ClinicalTrials.gov
Date: Jul 17, 2026
Trust tier: clinical-trials
License: ClinicalTrials.gov public registry record

SourceClinicalTrials.gov

Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer

Publisher: ClinicalTrials.gov
Date: Jun 24, 2026
Trust tier: clinical-trials
License: ClinicalTrials.gov public registry record

SourceClinicalTrials.gov

Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

Publisher: ClinicalTrials.gov
Date: Jul 2, 2026
Trust tier: clinical-trials
License: ClinicalTrials.gov public registry record